Reference number(s)
206-H

Quantity Limit
Soma

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Soma	carisoprodol

Indications

FDA-approved Indications

Soma

Soma is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.

Limitations of Use

Soma should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.

Initial Limit Quantity

Limits should accumulate across all drugs and strengths up to highest quantity listed depending on the order the claims are processed. Accumulation does not apply if limit is coded for daily dose.

The duration of 25 days is used for a 30-day fill period to allow time for refill processing.

These drugs are for short-term acute use; therefore, the intent is for prescriptions of the requested drug to be filled one month at a time; there should be no 3 month supplies filled.

Drug	1 Month Limit	3 Month Limit
Soma (carisoprodol)	84 tablets / 25 days	Does Not Apply

References

1. Soma [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; May 2023.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed September 5, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 09/05/2024).

Document History

Created: UM Development (JG) 03/2003

Revised: MB 08/2004; NG 08/2005; CT 08/2006, 07/2007; MS 07/2008; CT 08/2009, 12/2009, 06/2011, 03/2012, 03/2013; CF 01/2014; CT 01/2015; MS 01/2016 (no clinical changes); SF 01/2017 (no clinical changes); CF 09/2017 (no clinical changes); DS 09/2018 (no clinical changes); CF 09/2019 (no clinical changes); CM 09/2020 (removed brand Soma Compound and brand Soma Compound with Codeine from target box; no clinical changes); DS 09/2021 (no clinical changes); DFW 09/2022 (removed carisoprodol/aspirin); TM 09/2023 (no clinical changes); KMB 09/2024 (removed carisoprodol/aspirin/codeine phosphate from target drug box)

Reviewed: CRC 03/2003; CDPR/Medical Affairs MM 08/2004, 08/2005, 08/2006; WF 07/2007, 08/2008, 08/2009, 12/2009; KP 06/2011, 03/2012; KP 03/2013, 01/2014; LCB 01/2015; (CHART) 9/26/2019, 09/24/20, 09/30/2021, 09/22/2022, 09/28/2023, 09/26/2024

External Review: 12/2004; 12/2006, 02/2008, 12/2008, 10/2009, 10/2010, 10/2011, 08/2012, 06/2013, 03/2014, 06/2014, 04/2015, 04/2016, 04/2017, 02/2018, 02/2019, 02/2020, 12/2020, 12/2021, 12/2022, 12/2023, 12/2024